Overview of prescription omega-3 fatty acid products for hypertriglyceridemia

Postgraduate Medicine

Volumn 126, Issue 7, 2014, Pages 7-18

  Weintraub, Howard S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Hypertriglyceridemia; Omega 3 fatty acid; Triglycerides

Indexed keywords

2 DIACYLGLYCEROL ACYLTRANSFERASE; ACYL COENZYME A; ACYLTRANSFERASE; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; DOCOSAHEXAENOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; ETHYL EICOSAPENTAENOIC ACID; OMEGA 3 ACID ETHYL ESTER;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIARRHEA; DIET SUPPLEMENTATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERUCTATION; GENE EXPRESSION; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOGENESIS; META ANALYSIS (TOPIC); NAUSEA; OUTCOME ASSESSMENT; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); TASTE DISORDER; ANALOGS AND DERIVATIVES; BLOOD;

CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS;

EID: 84914811260     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.11.2828     Document Type: Article

References (80)

1. Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol. 2001;87(10):1174–1180.
2. Assmann G, Schulte H, von EA. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77(14):1179–1184.
3. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276(11):882–888.
4. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study [published correction appears in Circulation. 1998;97(19):1995]. Circulation. 1998;97(11):1029–1036.
5. National Cholestrol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholestrol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
6. Miller M, Stone NJ, Ballantyne C, et al; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20): 2292–2333.
7. Berglund L, Brunzell JD, Goldberg AC, et al; Endocrine Society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9): 2969–2989.
8. Cohen JD, Cziraky MJ, Cai Q, et al. 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999–2006. Am J Cardiol. 2010;106(7):969–975.
9. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009;169(6):572–578.
10. Stone NJ, Robinson J, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;63(25 Pt B):3024–3025]. J Am Coll Cardiol. 2014; 63(25 Pt B):2889–2934.
11. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006;189(1): 19–30.
12. Bays H. Fish oils in the treatment of dyslipidemia and cardiovascular disease. In: Kwiterovich PO Jr, ed. The Johns Hopkins Textbook of Dyslipidemia. Philadelphia, PA: Lippincott Williams & Wilkins/Wolters Kluwer Health; 2010:245–257.
13. Calder PC. n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond). 2004;107(1):1–11.
14. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br J Nutr. 2012;107(Suppl 2):S201–S213.
15. Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease [published correction appears in Circulation. 2003;107(3):512]. Circulation. 2002;106(21):2747–2757.
16. Kris-Etherton PM, Harris WS, Appel LJ; AHA Nutrition Committee, American Heart Association. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23(2):151–152.
17. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54(7):585–594.
18. Schunkert H, König IR, Kathiresan S, et al; CARDIoGRAM Consortium, Samani NJ. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43(4):333–338.
19. Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 2014;27(7):885–896.
20. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico [published corrections appear in Lancet. 2001;357(9256):642, and Lancet. 2007;369(9556):106]. Lancet. 1999;354(9177):447–455.
21. Gissi-HF Investigators; Tavazzi L, Maggioni AP, Marchili R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223–1230.
22. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015–2026.
23. ORIGIN Trial Investigators; Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–318.
24. Rauch B, Schiele R, Schneider S, et al; OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152–2159.
25. Yokoyama M, Origasa H, Matsuzaki M, et al; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis [published correction appears in Lancet. 2007;370(9583):220]. Lancet. 2007;369(9567):1090–1098.
26. Saito Y, Yokoyama M, Origasa H, et al; JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS) [published correction appears in Atherosclerosis. 2009;204(1):233]. Atherosclerosis. 2008;200(1):135–140.
27. Mozaffarian D, Marchioli R, Macchia A, et al; OPERA Investigators. Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial [published correction appears in JAMA. 2013;309(9):876]. JAMA. 2012;308(19):2001–2011.
28. Larsson SC, Orsini N, Wolk A. Long-chain omega-3 polyunsaturated fatty acids and risk of stroke: a meta-analysis. Eur J Epidemiol. 2012;27(12):895–901.
29. The Risk and Prevention Study Collaborative Group; Roncaglioni MC, Tombesi M, Avanzini F, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors [published correction appears in N Engl J Med. 2013;368(22):2146]. N Engl J Med. 2013;368(19): 1800–1808.
30. Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014.
31. Omtryg [package insert]. Arlington, VA: Trygg Pharma, Inc.; 2014.
32. Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2013.
33. Epanova [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014.
34. Omega-3 acid ethyl esters [package insert]. Spring Valley, NY: Par Pharmaceuticals Companies, Inc.; 2014.
35. Omega-3 acid ethyl esters [package insert]. Sellersville, PA: Teva Pharmaceuticals; 2014.
36. Kastelein JJ, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8(1):94–106.
37. Offman E, Marenco T, Ferber S, et al. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag. 2013;9:563–573.
38. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17(4):387–393.
39. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391–409.
40. US Food and Drug Administration. Drugs @FDA: Epanova. http://www.accessdata.fda.gov/Scripts/cder/drugsatfda/index. cfm?fuseactionSearch.DrugDetails. Accessed June 11, 2014.
41. US Food and Drug Administration. Drugs @FDA: Vascepa. http://www.accessdata.fda.gov/Scripts/cder/drugsatfda/index. cfm?fuseactionSearch.DrugDetails. Accessed June 11, 2014.
42. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4(5–6):385–391.
43. Pownall HJ, Brauchi D, Kilinç C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143(2):285–297.
44. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108(5):682–690.
45. National Institutes of Health. Efficacy study to treat subjects with severe hypertriglyceridemia. ClinicalTrials.gov. http://clinicaltrials.gov/show/ NCT01229566. Updated November 23, 2011. Accessed October 2, 2014.
46. Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013.
47. Davidson MH, Stein EA, Bays HE, et al; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(7):1354–1367.
48. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984–992.
49. Maki KC, Orloff DG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013;35(9):1400–1411.
50. RED BOOK. Lovaza Pricing Information. 2013. Truven Health Analytics. http://www.redbook.com/redbook/. Accessed August 14, 2014.
51. Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;13(1):37–46.
52. Braeckman RA, Bays HE, Ballantyne CM, Stirtan WG, Soni PN. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [abstract]. Circulation. 2013;128:A19343.
53. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6(1): 5–18.
54. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis [published correction appears in Curr Atheroscler Rep. 2012;14(1):93]. Curr Atheroscler Rep. 2011;13(6):474–483.
55. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110(6):763]. Circulation. 2004;110(2):227–239.
56. Panel AP. Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment. Diab Vasc Dis Res. 2006;3(2):S1–S12.
57. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med. 1981;141(9):1128–1131.
58. Ishida T, Ohta M, Nakakuki M, et al. Distinct regulation of plasma LDL cholesterol by eicosapentaenoic acid and docosahexaenoic acid in high fat diet-fed hamsters: participation of cholesterol ester transfer protein and LDL receptor. Prostaglandins Leukot Essent Fatty Acids. 2013;88(4):281–288.
59. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1–executive summary. J Clin Lipidol. 2014;8(5):473–488.
60. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmith- Kline; 2014.
61. Farxiga [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2014.
62. Jardiance [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2014.
63. Invokana [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2014.
64. Hilleman DE, Malesker MA. Potential benefits of icosapent ethyl on the lipid profile: case studies. Clin Med Insights Cardiol. 2014;8:13–15.
65. Castaldo RS. A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients. Postgrad Med. 2014;126(3):268–273.
66. Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova compared to Lovaza in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2012;6(6):573–584.
67. Itakura H, Yokoyama M, Matsuzaki M, et al; JELIS Investigators. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb. 2011;18(2):99–107.
68. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):1410–1422.
69. Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003;361(9356):477–485.
70. Cawood AL, Ding R, Napper FL, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212(1):252–259.
71. Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;13(1):37-46.
72. Nishio R, Shinke T, Otake H, et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis. 2014;234(1):114–119.
73. National Insitutes of Health. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin the primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE-IT). ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT01492361. Updated October 11, 2013. Accessed October 2, 2014.
74. National Institutes of Health. Outcomes Study of Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH). ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT02104817?termstrengthandomega-3&rank3. Updated September 24, 2014. Accessed October 2, 2014.
75. Zargar A, Ito MK. Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database. Metab Syndr Relat Disord. 2011;9(4):255–271.
76. Tur JA, Bibiloni MM, Sureda A, Pons A. Dietary sources of omega 3 fatty acids: public health risks and benefits. Br J Nutr. 2012;107(Suppl 2): S23–S52.
77. Weintraub H. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Atherosclerosis. 2013;230(2):381–389.
78. Weitz D, Weintraub H, Fisher E, Schwartzbard AZ. Fish oil for the treatment of cardiovascular disease. Cardiol Rev. 2010;18(5):258–263.
79. Truong P, Johnson C, Gabriel D. Variability of cholesterol and saturated fat content in dietary supplements [abstract]. Circulation. 2007;115(8):e238.
80. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 2013. Us Food and Drug Administration. http://www. accessdata.fda.gov/scripts/cder/ob/default.cfm. Accessed October 20, 2014.